Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 (vol 15, pg 429, 2009)

被引：2
|
作者：
Junttila, Teemu T. [1 ]
Akita, Robert W. [1 ]
Parsons, Kathryn [1 ]
Fields, Carter [1 ]
Phillips, Gail D. Lewis [1 ]
Friedman, Lori S. [1 ]
Sampath, Deepak [1 ]
Sliwkowski, Mark X. [1 ]
机构：
[1] Genentech Inc, Res Oncol, San Francisco, CA 94080 USA
来源：
CANCER CELL | 2011年 / 20卷 / 06期
关键词：
D O I：
10.1016/j.ccr.2011.12.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：818 / 818
页数：1
相关论文
共 50 条
  • [41] PI3k inhibitor GDC-0941 synergizes with standard of care therapies to induce growth inhibition and apoptosis of multiple myeloma cells
    Ebens, Allen
    Du, Changchun
    Slaga, Dion
    Munugalavadla, Veerendra
    Sun, Laura
    Berry, Leanne
    Mariathasan, Sanjeev
    CANCER RESEARCH, 2009, 69
  • [42] Role of P-glycoprotein and Bcrp1 in the brain penetration and activity of the Novel PI3K inhibitor GDC-0941
    Salphati, Laurent
    Lee, Leslie
    Pang, Jodie
    Plise, Emile G.
    Zhang, Xiaolin
    DRUG METABOLISM REVIEWS, 2010, 42 : 300 - 300
  • [43] The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria
    Rohlenova, Katerina
    Neuzil, Jiri
    Rohlena, Jakub
    BIOLOGICAL CHEMISTRY, 2016, 397 (07) : 607 - 615
  • [44] HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
    Pan, Linghui
    Li, Jinling
    Xu, Qi
    Gao, Zili
    Yang, Mao
    Wu, Xiaoping
    Li, Xuesen
    MEDICINE, 2024, 103 (24) : e38508
  • [45] GDC-0941 and ABT-737 cooperate to sensitize isolated mitochondria from PI3K mutant cells
    Buron, N.
    Porceddu, M.
    Disley, D.
    Torrance, C.
    Borgne-Sanchez, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 47 - 47
  • [46] The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells
    Munugalavadla, Veerendra
    Berry, Leanne
    Du, Changchun
    Mariathasan, Sanjeev
    Slaga, Dion
    Sun, Laura
    Chesi, Marta
    Bergsagel, Peter Leif
    Ebens, Allen J.
    BLOOD, 2009, 114 (22) : 1456 - 1456
  • [47] Anti-tumour efficacy of the PI3K inhibitor GDC0941, the dual PI3K/mTOR inhibitor GDC0980 and the MEK inhibitor GDC0973 as single agents and in combination in endometrial carcinomas
    Aslan, O.
    Farrelly, A. M.
    Stordal, B.
    Hennessy, B. T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S736 - S736
  • [48] Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors
    Chakrabarty, Anindita
    Bhola, Neil E.
    Sutton, Cammie
    Ghosh, Ritwik
    Kuba, Maria Gabriela
    Dave, Bhuvanesh
    Chang, Jenny C.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2013, 73 (03) : 1190 - 1200
  • [49] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
  • [50] GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab
    Ventriglia, J.
    Laterza, M. M.
    Capasso, A.
    Belli, V.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Diana, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2016, 27
12345